Clinical trial simulations based on a meta-analysis of studies in patients with locally advanced and/or metastatic adenocarcinoma pancreatic cancer receiving gemcitabine (GEM) alone or in combination. Objectives: To develop a model to: (1) describe median overall survival (mOS) in trials with locally advanced and/or metastatic adenocarcinoma pancreatic cancer treated with GEM alone and in combination; (2) to simulate predictive distributions based on Von Hoff 2013 1 and assess the probability of the results in a future study; and 3) to compare predictions based on mOS and overall survival hazard ratios (OS-HR).
